Advances in Pharmacoepidemiology and Drug Safety

Da-Yong Lu

Publications

• Editorial
  Cost-effectiveness Considerations of Individualized Cancer Chemotherapy
  Author(s): Da-Yong Lu, Ting-Ren Lu and Hong-Ying WuDa-Yong Lu, Ting-Ren Lu and Hong-Ying Wu
  
  The running cost for clinical cancer treatment has risen dramatically. It is a huge burden to government fiscal budgets and cancer patients’ medical expenditure. Previously, we often create new drug and methodology of high cost and waste human resources for development of many less effects and expensive anticancer drugs or other sophisticated methodologies. These efforts will greatly increase therapeutic costs. Now some countries, such as USA or Japan, are overburden with high expense of medical resources in human diagnosis and therapy, especially for human cancer therapy. One of the major obstacles to controlling cancer growth and metastases is the inappropriate use of anticancer drugs. Treatment using individualized cancer chemotherapy (ICC) has been attracting increasing attention and will continue to show beneficial outcomes in the future. Increasing efforts to develop ICC s.. View More»
  DOI: 10.4172/2167-1052.1000e121

  Abstract PDF